Dra. Yuri Reyes Mendez Psiquiatría Clínica y Forense

11/08/2026

10/08/2026

14/07/2026

🧠 La ansiedad y la depresión son algunas de las principales afectaciones que enfrentan las personas trans como consecuencia de la violencia, el rechazo y la discriminación que viven en distintos ámbitos de su vida.

La psicóloga Claudia Gastelo señaló que estas problemáticas no se originan por la identidad de género, sino por las experiencias de transfobia y las barreras para acceder a derechos como la educación, el empleo y la salud.

Explicó que el acompañamiento psicológico y un enfoque basado en la empatía y los derechos humanos contribuyen al bienestar emocional de esta población.

📝: Fernando Guerrero
📷: Cortesía / Ilustrativa

30/06/2026

https://www.facebook.com/share/v/1FuzkQsTbw/?mibextid=wwXIfr Programa completo CORAZÓN Y ESTRÉS CRÓNICO

30/06/2026

24/06/2026

02/06/2026

Depression is not just a “chemical imbalance”, it’s also a plasticity problem. Research shows that neurotrophic factors like BDNF (brain-derived neurotrophic factor) act as the brain’s “growth signals,” supporting neuron survival, synaptic strength, and neurogenesis.

In depression:
• BDNF levels are often reduced
• Brain regions like the hippocampus and prefrontal cortex show atrophy
• Neural connections become less flexible

Most antidepressant treatments, from medications to behavioral interventions, work by restoring neuroplasticity and increasing neurotrophic signaling over time.

This is why recovery isn’t instant.
The brain isn’t just “balancing chemicals”, it’s rebuilding connections. Not everyone gets access to what I share about mental health behind the scenes. If you don’t want to miss it, join now in the early stages before it grows: https://www.patreon.com/betterbrain

🧠 Heal the brain → change the mind.

Reference: Levy et al., Neurotrophic factors and neuroplasticity pathways in depression, Psychopharmacology (2018).

12/05/2026

Current attention-deficit/hyperactivity disorder (ADHD) subtypes, based on parent-reported symptoms, are not very useful for clinical predictions or research breakthroughs. This study identified new ADHD subtypes using computerized attention-based tasks and compared these new subtypes’ responses to 2 ADHD medications: methylphenidate (stimulant) and atomoxetine (nonstimulant). A subtype with a more impulsive, error-prone style had higher resting heart rates and EEG differences and responded well to both medications. A subtype with more lapses in sustained attention responded well only to methylphenidate. These results are a step toward targeting treatments based on attention testing. These novel subtypes could also help understand underlying biological mechanisms. https://twp.ai/bWU9aK

A podcast interview with the author is available: https://twp.ai/S99fCC

This article is also associated with an editorial: https://twp.ai/IlpAo4